(NasdaqGM:GANX), Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of action Completed enrollment of 21 participants in Phase 1b study evaluating GT-02287 in Parkinson's Disease with or without GBA1 mutations during 3Q 2025 Received approval from the Australian health […]
(NASDAQ:ABOS), Expect decision regarding the advancement of an AB oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026 Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026 Cash, cash equivalents and marketable securities of $136.1 million as of Sept.
(NasdaqGM:OCUL), BEDFORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in November and December, 2025. Jefferies Global Healthcare Conference in London:Fireside Chat Date: Tuesday, November 18, 2025Fireside Chat Time: 2:30 – 2:55
(NASDAQ:SMTI), Net Revenue Increased 22% Year-Over-Year in Q3; Increased 25% Year-Over-Year in First Nine Months of 2025 FORT WORTH, TX, Nov. 12, 2025 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce
Regular Quarterly Dividend of $0.35 Per Share and Supplemental Quarterly Dividend of $0.01 Per Share Payable January 30, 2026 MSC Income Fund, Inc. (NYSE: MSIF) (the “Fund”) is pleased to announce that its Board of Directors declared a regular quarterly cash dividend of $0.35 per share payable in January 2026, which will be payable as
Bot Auto, the autonomous freight company pioneering a Transportation-as-a-Service (TaaS) model for the future of logistics, today announced the placement of a comprehensive insurance program that supports the safe scaling and deployment of its autonomous truck fleet. The program establishes new benchmarks for transparency, insurability, and operational accountability in commercial transportation. https://mma.prnewswire.com/media/2819744/Bot_Auto_TX__Humanless_Bot_Auto_Truck.jpg The insurance program-underwritten
(NASDAQ:IRD), – Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated vision – – Successful FDA RMAT meeting provides the potential for an accelerated regulatory pathway to approval for OPGx-LCA5 – – OPGx-BEST1 gene therapy program underway with recruitment ongoing in Phase 1/2 trial for
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) — Dispatch Energy LLC (“Dispatch”), a full-service provider of distributed energy solutions, today announced the acquisition of Green Lantern Solar (“GLS”), an integrated provider, developer, owner and operator of solar photovoltaic assets. Dispatch will acquire over 64 solar and battery storage projects from GLS, totalling 208.9 MWdc, at
Bunzl Canada's annual Delivery & Warehouse Appreciation Week recognizes the dedication of drivers and warehouse teams, fostering a culture of respect, pride, and trust that supports its Great Place To Work(R) certification. BURLINGTON, Ontario, Nov. 12, 2025 (GLOBE NEWSWIRE) — Bunzl Canada is proud to announce that it has once again achieved the prestigious Great
(NasdaqGM:TNGX), BOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday, November 19 at 4:30-4:55 PM GMT / 11:30-11:55am ET. The live